Navigation Links
Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
Date:4/5/2011

inances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate partners for development, commercial manufacturing and marketing and sales activities for the Company's partnered programs; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
5. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
6. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
9. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
10. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
11. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... variations, development of sequencing technologies, and their applications. ... well as companies developing them. Various applications of ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ) ... "Gene Therapy - Technologies, Markets and Companies" ... therapy are difficult to estimate as there is only ... in China since 2004. Gene ... estimates are based on epidemiology of diseases to be ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Project is Aimed at Developing New Screening Methods and Holds Significant, Potential ... ... Killer, - Biomarker Project holds significant potential for ... detect the disease before ...
... in 24 European ... Countries, - Competitors Precluded from Immediate Commercialization of ... ... &,Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) announces that the,European Patent Office (EPO) granted on ...
... to Aida Pharmaceuticals, ... Inc.,s Product ... (OTC Bulletin Board: AIDA) today announced that it,has signed two ... the leading microbiology research institutes in the People,s,Republic of China, ...
Cached Biology Technology:Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 2Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 3Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 2Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 3Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 2Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... A team of international molecular scientists, led by a ... which cells communicate change for example their location during ... adjacent cells. The discovery sheds new light on cell ... to combat diseases such as cancer, rheumatoid arthritis and Alzheimer,s ...
... the behaviour of invasive ants in northern Australia, finding ... networks, CSIRO has recognised the outstanding work of some ... in Melbourne. The CSIRO Medals are awarded each year ... contributions to the organisation. Awarded since 1985, the CSIRO ...
... of altruism has long puzzled researchers and has mainly ... now because I expect there to be some long-term ... at the Primate Research Institute (PRI) and the Wildlife ... altruistically help conspecifics, even in the absence of direct ...
Cached Biology News:Milestone discovery in cell behaviors 2CSIRO medal winners 2CSIRO medal winners 3Chimpanzees help each other on request but not voluntarily 2
...
... antibody recognizes 30% of IgM-rheumatoid ... It does not cross-react with IgM, ... factor nor with pooled F(Ab)2 fragments. ... ELISA to detect rheumatoid factor. Product ...
... ,human IgG subclass 1 100% ,human IgG subclass ... 100% ,human IgG subclass 4 ... 100% ,human IgG Fc ... 0.04% ,human IgG Fab ...
...
Biology Products: